Skip to main content
Log in

Educational Paper: Aspects of clinical pharmacology in children—pharmacovigilance and safety

  • Review
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Adverse drug reactions (ADRs) are a significant problem in children, affecting one in ten children in hospital. Within the community, one in 500 children will experience an adverse drug reaction each year. Pharmacovigilance has been useful in detecting suspected ADRs. However, most ADRs are unreported and often not suspected. Education of health professionals in relation to drug toxicity improves the reporting rate of suspected ADRs. Clinical trials are useful to evaluate the efficacy of drugs. They are, however, not the best way of looking at ADRs where surveillance following the widespread use of a drug is more appropriate. Alongside work by the regulatory agencies, independent investigators have helped collate data. This information has been useful in developing guidelines to prevent further cases of drug toxicity. Greater awareness and understanding of drug toxicity in children should result in more rational prescribing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aagaard L, Blicher Weber C, Holme Hansen E (2010) Adverse drug reactions in the paediatric population in Denmark. Drug Saf 33:327–339

    Article  PubMed  Google Scholar 

  2. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I (2011) Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child 96:874–880

    Article  PubMed  Google Scholar 

  3. Aldea A, García Sánchez-Colomer M (2012) Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. Eur J Clin Pharmacol 68:1329–1338

    Article  PubMed  CAS  Google Scholar 

  4. Alkahtani S, Sammons H, Choonara I (2010) Epidemics of acute renal failure in children (diethylene glycol toxicity). Arch Dis Child 95:1062–1064

    Article  PubMed  Google Scholar 

  5. Anderson M, Choonara I (2010) A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period. Arch Dis Child 95:731–738

    Article  PubMed  Google Scholar 

  6. Bárzaga Arencibia Z, López Leyva A, Mejías Peña Y, González Reyes AR, Fernández Manzano E, Choonara I (2012) Pharmacovigilance in children in Camagüey Province, Cuba. Eur J Clin Pharmacol 68:1079–1084

    Article  PubMed  Google Scholar 

  7. Bárzaga Arencibia Z, Novoa Sotomayer D, Mollinedo C, Choonara I, Fernández Manzano E, López Leyva A (2010) Adverse drug reactions in children in Camagüey Province, Cuba. Arch Dis Child 95:474–477

    Article  PubMed  Google Scholar 

  8. Belliard CR, Sibille G (2006) Anaphylactoid shock or precipitation of calcium-ceftriaxone in a premature newborn. A case report. Arch Pediatr 14:199–200

    Article  PubMed  Google Scholar 

  9. Bray RJ (1998) Propofol infusion syndrome in children. Paediatr Anaesth 8:491–499

    Article  PubMed  CAS  Google Scholar 

  10. Choonara I (2006) Paediatric pharmacovigilance. Paediatr Perinat Drug Ther 7:50–53

    Article  Google Scholar 

  11. Choonara I (2011) Safety of new medicines in young children. Arch Dis Child 96:872–873

    Article  PubMed  Google Scholar 

  12. Clarkson A, Conroy S, Burroughs K, Choonara I (2004) Surveillance for adverse drug reactions in children: a paediatric regional monitoring centre. Paediatr Perinat Drug Ther 6:20–23

    Article  Google Scholar 

  13. Clavenna A, Bonati M (2009) Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child 94:724–728

    Article  PubMed  CAS  Google Scholar 

  14. de Vries TW, van Roon EN (2009) Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. Arch Dis Child 95:1023–1026

    Article  Google Scholar 

  15. Dieppe PA, Ebrahim S, Martin RM, Jüni P (2004) Lessons from the withdrawal of rofecoxib. BMJ 329:867–868

    Article  PubMed  Google Scholar 

  16. Donat JF, Bocchini JA Jr, Gonzalez E, Schwendimann RN (1979) Valproic acid and fatal hepatitis. Neurology 29:273–274

    Article  PubMed  CAS  Google Scholar 

  17. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB (1987) Valproic acid hepatic fatalities: a retrospective review. Neurology 37:379–385

    Article  PubMed  CAS  Google Scholar 

  18. Dunn PM (1964) The possible relationship between the maternal administration of sulphamethoxypyridazine and hyperbilirubinaemia in the newborn. J Obstet Gynecol Br Commonwealth 71:128–131

    Article  CAS  Google Scholar 

  19. Edwards IR, Biriell C (1994) Harmonisation in pharmacovigilance. Drug Saf 10:93–102

    Article  PubMed  CAS  Google Scholar 

  20. Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:180

    Article  PubMed  CAS  Google Scholar 

  21. Hawcutt DB, Mainie P, Riordan A, Smyth RL, Pirmohamed M (2012) Reported paediatric adverse drug reactions in the UK 2000–2009. Br J Clin Pharmacol 73:437–446

    Article  PubMed  CAS  Google Scholar 

  22. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M (2001) Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 52:77–83

    Article  PubMed  CAS  Google Scholar 

  23. Impicciatore P, Pandolfini C, Bosetti C, Bonati M (1998) Adverse drug reactions in children: a systematic review of published case reports. Paediatr Perinat Drug Ther:27–32

  24. Kimland E, Rane A, Ufer M, Panagiotidis G (2005) Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf 14:493–499

    Article  PubMed  Google Scholar 

  25. Kunac D, Tatley MV, Grimwood K, Reith DM (2012) Active surveillance of serious adverse drug reactions in New Zealand children. ADC Online First, published May 6

  26. Giles H MCc (1965) Encephalopathy and fatty degeneration of the viscera. Lancet 1:1075

    Google Scholar 

  27. Medicines Control Agency (1998) Current problems in pharmacovigilance. Vigabatrin (Sabril) and visual field defects 24:1

  28. Nor Aripin KNB, Choonara I, Sammons HM (2012) Systematic review of safety in paediatric drug trials published in 2007. Eur J Clin Pharmacol 68:189–194

    Article  PubMed  Google Scholar 

  29. Parke TJ, Stevens JE, Rice ASC et al (1992) Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 305:613–616

    Article  PubMed  CAS  Google Scholar 

  30. Sammons HM, Gray C, Hudson H et al (2008) Safety in paediatric clinical trials—a 7-year review. Acta Paediatr 97:474–477

    Article  PubMed  CAS  Google Scholar 

  31. Silverman WA, Andersen DH, Blanc WA, Crozier DN (1958) A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 18:614–621

    Google Scholar 

  32. Starko KM, Ray G, Dominguez LB, Stromberg W, Woodall DF (1980) Reye’s syndrome and salicylate use. Pediatrics 66:859–864

    PubMed  CAS  Google Scholar 

  33. Stiefel G, Besag FMC (2010) Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 33:821–842

    Article  PubMed  CAS  Google Scholar 

  34. Sutherland JM (1959) Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J Dis Child 97:761–767

    PubMed  CAS  Google Scholar 

  35. Tullus K (2011) Safety concerns of angiotensin II receptor blockers in preschool children. Arch Dis Child 96:881–882

    Article  PubMed  Google Scholar 

  36. Weiss CF, Glazko AJ, Weston JK (1960) Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. New Engl J Med 262:787–794

    Article  PubMed  CAS  Google Scholar 

  37. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E (2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363:1341–1345

    Article  PubMed  CAS  Google Scholar 

  38. WHO (2008) Ceftriaxone: fatal outcome with calcium-containing solutions. WHO Drug Inf 22:193–194

    Google Scholar 

  39. Wieseler B, McGauran N, Kaiser T (2010) Drug studies: a tale of hide and seek. BMJ 341:809–814

    Article  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Imti Choonara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choonara, I. Educational Paper: Aspects of clinical pharmacology in children—pharmacovigilance and safety. Eur J Pediatr 172, 577–580 (2013). https://doi.org/10.1007/s00431-012-1871-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-012-1871-9

Keywords

Navigation